DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pharmasset
Pharmasset
Sofosbuvir
Original Article Antiviral Activity of Nucleoside Analogues Against Norovirus
What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
Progress Report on Access to Hepatitis C Treatment
PSI-7977, an Unpartnered Uracil Nucleotide Analog, Has Recently Been Advanced Into Two Phase 3 Studies in Genotype 2 and 3 Patients
Antiviral Drugs in the Treatment of Aids: What Is in the Pipeline ?
Case in Point
Acquisition Agreement for Pharmasset -- Current Agreements
Investment Thesis for Gilead Sciences, Inc
Intellectual Property India
| Hao Wakati Mwithiumai Una Minut
Evaluating Gilead's Pricing Strategy of Sovaldi
Ledipasvir and Sofosbuvir for 8 Or 12 Weeks for Chronic HCV Without Cirrhosis Kris V
The Grounds for Opposing Patent Applications on Sofosbuvir
United States Securities and Exchange Commission Form
Intellectual Property India
Profile of Charles M. Rice, Ralf F. W. Bartenschlager, and Michael J. Sofia, 2016 Lasker–Debakey Clinical Medical Research
GILEAD SCIENCES: PRICE GOUGER, TAX DODGER Ireland
Top View
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Advancing Therapeutics. Improving Lives
17A ___Merck & Co., Inc
Bristol Myers Squibb Co (Bmy)
GILEAD SCIENCES, INC. V. MERCK &
In the United States District Court for the District of Delaware
Sofosbuvir Turns 5 Years Old: the Vast Majority of People with Chronic Hepatitis C Still Have Not Been Treated Fact Sheet
Gilead Sciences to Acquire Pharmasset, Inc
HIV-Treatment-Prevention-CLE-2B
Programand ABSTRACTS
2011 Pipeline Report Second Edition